New River Pharmaceuticals — FBR Investor Conference 2005
18 slides from New River Pharmaceuticals's conference presentation, Jun 1, 2005

Slide 1: FBR Investor Conference
FBR Investor Conference June 1, 2005 RJ Kirk (Chairman and CEO) Krish Krishnan (CFO/COO)

Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward-looking statements that reflect management’s current views as to the Company’s clinical trials, regulatory approval process, product development, research programs and other future events and operations. These forward-looking statement

Slide 3: Investment Thesis
Investment Thesis A platform technology yielding proprietary products that offer significant clinical advantages with low technical risk and shorter development pathway, facing timely market demand, in a favorable regulatory climate.

Slide 4: New River's Carrierwave Technology
New River’s Carrierwave™ Technology Active Drug Peptide(s) New Molecular Entity n Novel, proprietary drugs are created by covalently binding an active drug to one or more natural amino acids that are Generally Regarded As Safe (GRAS) n Active drug is released from conjugate enzymatically and is abso

Slide 5: Potential Bioactive Enhancements
Potential Bioactive Enhancements n Increased bioavailability n Increased stability n Reduced variability n Decreased toxicity n Abuse resistance n Overdose protection

Slide 6: Targeting product classes that need improvement
NSAIDS OPIOIDS THYROID HORMONE REPLACEMENT ANTIVIRALS STIMULANTS Targeting product classes that need improvement

Slide 7: Product Pipeline
Product Pipeline Compound Indication Timeline Objective NRP104 ADHD NDA by end of 2005 n Abuse Resistance and Overdose Protection n Comparable efficacy NRP290 Acute Pain IND in Q2 2005 n Abuse Resistance and Overdose Protection n Comparable efficacy NRP369 Chronic Pain IND in Q4 2005 n Abuse Resista

Slide 8: Research Efforts using Carrierwave Technology
Research Efforts using Carrierwave™ Technology n Product that provides a more predictable level of the active hormone compared to currently marketed products. Therapeutic Area: Hypothyroidism n Product that provides reduced toxicity compared to currently marketed NSAIDs. Therapeutic Area: Inflammati

Slide 9: Expanding Capabilities through Collaboration
Expanding Capabilities through Collaboration n Shire Pharmaceuticals, Inc. (“Shire”) • NRP104 – novel stimulant treatment for ADHD, partnered with Shire Ø New River primarily responsible for clinical and manufacturing development Ø Shire primarily responsible for commercialization; leverages Shire’s

Slide 10: NRP108
NRP108 n Based on NRP104 n Therapeutic Area: Major Depressive Disorders n Pre-Clinical n Subject to previously announced Collaboration Agreement with Shire Pharmaceuticals, Inc.

Slide 11: NRP290 market potential
We believe that the market potential for this product ~ 5 billion doses/year* * Based on IMS retail data and internal estimates NRP290

Slide 12: NRP290: Preclinical Overview
NRP290: Preclinical Overview n Bioavailability of hydrocodone and hydromorphone levels in NRP290 comparable to hydrocodone bitartrate in dogs n Reduced bioavailability of hydrocodone and hydromorphone at increasing dosages n Reduced bioavailability via intranasal and intravenous routes n Resistant t

Slide 13: Oral Bioavailability in Dogs
Oral Bioavailability in Dogs Concentration-time curves of hydrocodone and hydromorphone following oral administration of NRP290 or hydrocodone bitartrate (n=3, mean concentrations +/- S.D., dose - -0.295 mg/kg HC base, HED 16 mg hydrocodone bitartrate) • Hydrocodone (AUC = 60% and Cmax = 51%) • Hydr

Slide 14: Dose Escalation in Rats
Dose Escalation in Rats Bioavailability per HED at escalating oral doses of NRP290 and hydrocodone bitartrate in rats C max -HED curves (n=3 per data point) AUC inf -HED curves (n=3 per data point)

Slide 15: Intravenous Bioavailability in Rats
Intravenous Bioavailability in Rats Concentration-time curves of hydrocodone following intravenous administration of NRP290 or hydrocodone bitratrate (n=5, mean concentrations +/- S.D., dose - 1 mg/kg HC base) • Hydrocodone (AUC = 31% and Cmax = 22%) • Observed decreased bioavailability by IV route

Slide 16: Intranasal Bioavailability in Rats
Intranasal Bioavailability in Rats Concentration-time curves of hydrocodone following intranasal administration of NRP290 or hydrocodone bitratrate (n=4, mean concentrations +/- S.D., dose - 1 mg/kg HC base) • Hydrocodone (AUC = 19% and Cmax = 9%) • Observed decreased bioavailability by IN route

Slide 17: NRP290 Stability
NRP290 Stability n 0-5% release under mild conditions (vinegar, baking soda) n Less than 50% in concentrated acid or base with heat n Up to 20% under enzymatic conditions (1 hour) n Less than 50% release in numerous household chemicals with heat n Difficult to recover/extract hydrolyzed hydrocodone

Slide 18: ee a
ee a . Se % . Coe NE W RIVER PHARMACEUTICALS
Source: SEC EDGAR · 8-K filed Jun 1, 2005
More decks from New River Pharmaceuticals Inc
Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference 20078 slides · Feb 6, 2007
Bear Stearns 19th Annual Investor Conference 200614 slides · Sep 12, 2006
Technical Presentation (June 2006)46 slides · Jun 26, 2006
Technical Presentation (June 2006)8 slides · Jun 20, 2006
Technical Presentation (June 2006)19 slides · Jun 19, 2006
Merrill Lynch Healthcare Conference 200610 slides · Feb 7, 2006